Back

The prognostic role of a structured patient education programme among patients hospitalised for heart failure with reduced ejection fraction: To know or not to know, that is the question

30 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Diagnostic and prognostic biomarkers in heart failure (2) Multidisciplinary Interventions ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Fanni Banfi-Bacsardi

Gottsegen National Cardiovascular Center, Budapest (Hungary)

5 More presentations in this session

Presentation thumbnail
Digoxin initiation in advanced heart failure with reduced ejection fraction and atrial fibrillation: a nationwide target trial emulation study
Doctor C. Basile (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Applicability of mineralocorticoid receptor antagonist trials to real-world patients with heart failure across the ejection fraction spectrum
Doctor B. Beer (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Impact of a pre-discharge checklist on temporal trends in gdmt prescription and clinical events in patients with heart failure
Assistant Professor J. Jang (Incheon, KR)
Abstract Slides Video
Presentation thumbnail
Temporal trends and determinants of heart failure therapy after myocardial infarction: a PROFID subanalysis
Doctor A. Sepehri Shamloo (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
“Hold the drug, strength tomorrow”: The prognostic effect of therapy adherence after a hospitalisation for heart failure with reduced ejection fraction
Doctor P. Schaffer (Budapest, HU)
Abstract Slides

Access the full session

Session thumbnail
Diagnostic and prognostic biomarkers in heart failure (2)

The Event

Event poster

ESC Congress 2026

30 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
The role of a structured patient education programme in the complex care of patients with heart failure
29 August 2025
thumbnail
Congress Presentation
Association of an early multidisciplinary HF pathway and inpatient rehabilitation with 1-year survival: a four-group real-world analysis (2020–2025)
28 August 2026
thumbnail
Congress Presentation
Outcomes of sacubitril/valsartan plus SGLT2 inhibitors versus SGLT2 inhibitors in heart failure with reduced ejection fraction: a propensity-matched real-world analysis
28 August 2026
thumbnail
Congress Presentation
Implementation of a transitional care programme for heart failure and its impact on 30-day readmissions and emergency department visits
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources